Skip to main content
Longevity Stack
Peptides/Metabolic

Retatrutide

Grade A

Phase II trial results showed ~24% mean weight loss at 48 weeks at the 12 mg dose — markedly exceeding tirzepatide and prior GLP-1 monotherapies. Currently in Phase III; not yet FDA-approved but expected to be a landmark obesity and metabolic therapy.

Category
Metabolic
Evidence grade
A
Route
Subcutaneous injection
Half-life
~6 days (supports once-weekly dosing)
Typical dose
Titrated 2 mg → 4 mg → 8 mg → 12 mg
Frequency
Once weekly
Cycle length
Ongoing; weight regain occurs on cessation
Best timing
Same day each week; any time of day
Why Retatrutide matters

Triple GIP/GLP-1/glucagon agonist. Phase II trial results showed ~24% mean weight loss at 48 weeks at the 12 mg dose — markedly exceeding tirzepatide and prior GLP-1 monotherapies. Currently in Phase III; not yet FDA-approved but expected to be a landmark obesity and metabolic therapy.

  • ~24% mean weight loss at 48 weeks (Phase II)
  • Marked improvements in HbA1c, blood pressure, ApoB and liver fat
  • Convenient once-weekly dosing
  • Likely best-in-class cardiometabolic profile
Typical dose
Titrated 2 mg → 4 mg → 8 mg → 12 mg
Frequency
Once weekly
Route
Subcutaneous injection
Evidence
Grade A

Mechanism of Action

First-in-class triple agonist of GIP, GLP-1, and glucagon receptors. The GLP-1 and GIP arms drive glucose-dependent insulin secretion and satiety; the glucagon arm increases energy expenditure — producing the largest weight-loss effect of any incretin to date.

Typical Protocol

Dose
Titrated 2 mg → 4 mg → 8 mg → 12 mg
Frequency
Once weekly
Duration
Ongoing; weight regain occurs on cessation
Timing
Same day each week; any time of day
Route
Subcutaneous injection
Half-life
~6 days (supports once-weekly dosing)

Educational reference only — not medical advice.

Pharmacokinetics & Dosing Rationale

Retatrutide is administered subcutaneous injection with an approximate systemic half-life of ~6 days (supports once-weekly dosing). Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (Once weekly) is designed to match receptor kinetics rather than plasma exposure. First-in-class triple agonist of GIP, GLP-1, and glucagon receptors. The GLP-1 and GIP arms drive glucose-dependent insulin secretion and satiety; the glucagon arm increases energy expenditure — producing the largest weight-loss effect of any incretin to date.

How to Administer

  1. Route: Subcutaneous injection. Typical starting dose Titrated 2 mg → 4 mg → 8 mg → 12 mg, Once weekly.
  2. Timing: Same day each week; any time of day — keep it the same each dosing day to make effects legible.
  3. Cycle length: Ongoing; weight regain occurs on cessation. Reassess with bloods and symptom logs before repeating.
  4. Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.

Reconstitution & Injection Technique

  1. Reconstitute lyophilised powder with bacteriostatic water (0.9% benzyl alcohol) — sterile water is acceptable but shortens shelf life to ~72 hours.
  2. Typical dilution: add 2 mL of bacteriostatic water to a 5 mg vial → 2.5 mg/mL; a 10-unit insulin syringe mark = 0.25 mg.
  3. Inject the diluent slowly against the vial wall — never onto the powder — and gently swirl. Do not shake; peptides denature under shear.
  4. Once reconstituted, store upright in the refrigerator (2–8 °C) and use within 30 days.
  5. Draw the dose with an insulin syringe (29–31G, 8 mm), swab the site with alcohol, pinch subcutaneous tissue on the abdomen or thigh, inject at 90°.

Sterile technique is not optional. Use a fresh needle for every injection.

Cycling & Stacking Strategy

  • Standard protocol: Titrated 2 mg → 4 mg → 8 mg → 12 mg, Once weekly, for Ongoing; weight regain occurs on cessation.
  • Ramp up: start at the lower end of the dose range for the first 7–10 days to gauge tolerance and side effects before titrating.
  • Break periods let receptor sensitivity and endogenous feedback loops normalise — running back-to-back cycles without a wash-out erodes the effect.
  • Common stack: Creatine monohydrate, Whey protein, Vitamin D3 + K2. Introduce one compound at a time so you can attribute effect and side effect.

Who This Is For

Good candidates
  • Adults with a specific, measurable goal aligned to triple gip/glp-1/glucagon agonist.
  • People who already have baseline bloods, a training routine and a sleep protocol in place.
  • Users who can commit to a full cycle, log the protocol, and re-test biomarkers to evaluate response.
  • Anyone working with a clinician willing to supervise off-label or investigational protocols.
Not appropriate for
  • Anyone with active or recent malignancy, or a strong family cancer history where mechanism is angiogenic or growth-promoting.
  • Pregnant or breastfeeding women — human safety data is absent for almost all research peptides.
  • Adolescents and anyone under 21 whose endocrine axis is still developing.
  • People unwilling to run baseline and post-cycle bloods.
  • Specific contraindications for Retatrutide: Personal or family history of medullary thyroid carcinoma; Multiple Endocrine Neoplasia type 2; Pregnancy and lactation; Prior severe reaction to GLP-1 agonists.

What to Monitor

HbA1c & fasting glucoseBaseline and every 8–12 weeks — expect improvement; watch for hypoglycaemia if combined with insulin or sulfonylureas.
Lipid panelBaseline and at 12 weeks — GLP-1 class typically improves triglycerides and LDL.
Body composition (DEXA)Track lean mass loss — mitigate with resistance training and ≥1.6 g/kg protein.
Kidney function (eGFR, creatinine)Baseline and every 6 months if used chronically.
Take it with you

Download a printable version of this checklist to log baseline, weekly and post-cycle results.

Reported Benefits

  • ~24% mean weight loss at 48 weeks (Phase II)
  • Marked improvements in HbA1c, blood pressure, ApoB and liver fat
  • Convenient once-weekly dosing
  • Likely best-in-class cardiometabolic profile

Safety Profile

Side effects
  • Nausea, vomiting, diarrhea (especially during titration)
  • Injection site reactions
  • Reduced appetite to the point of inadequate protein intake — pair with resistance training and protein targeting
  • Theoretical pancreatitis and gallbladder risk (class effect)
Contraindications
  • Personal or family history of medullary thyroid carcinoma
  • Multiple Endocrine Neoplasia type 2
  • Pregnancy and lactation
  • Prior severe reaction to GLP-1 agonists
Known interactions
Open interactions explorer →
Insulin and sulfonylureasRisk of hypoglycemia — dose reduction usually required.
Oral medicationsDelayed gastric emptying may alter absorption; separate timing for narrow-therapeutic-index drugs.
Storage & handling
  • Unreconstituted vials: store at 2–8 °C long-term; brief room-temperature excursions during shipping are usually acceptable.
  • Reconstituted vials: refrigerate at 2–8 °C, protect from light, use within 30 days.
  • Freezing: acceptable for unreconstituted powder if long-term storage is required; avoid repeated freeze-thaw cycles.
  • Never use a vial that appears cloudy, discoloured or has visible particulates.

Common Mistakes

  • Chasing a bigger dose instead of consistency — Retatrutide outcomes track cumulative exposure, not peak concentration.
  • Skipping baseline bloods, so there is no way to know whether the cycle actually moved a biomarker.
  • Stacking three or four novel compounds at once — you lose the ability to attribute any effect or side effect.
  • Ignoring the training, sleep and nutrition fundamentals that are prerequisites for every peptide protocol.
  • Reusing insulin needles or failing to rotate injection sites — a preventable cause of local reactions and lipohypertrophy.

Evidence Grade — A

Grade A — supported by multiple randomised human trials or an approved regulatory indication. Mechanism, dosing and safety are well characterised in humans.

Below are the primary references used to grade Retatrutide. Follow the links for full-text where available and cross-check against the current literature.

Frequently Asked Questions

What is the typical Retatrutide protocol?+

Titrated 2 mg → 4 mg → 8 mg → 12 mg, Once weekly, for Ongoing; weight regain occurs on cessation. Route: Subcutaneous injection. Timing: Same day each week; any time of day. Half-life: ~6 days (supports once-weekly dosing).

How does Retatrutide work?+

First-in-class triple agonist of GIP, GLP-1, and glucagon receptors. The GLP-1 and GIP arms drive glucose-dependent insulin secretion and satiety; the glucagon arm increases energy expenditure — producing the largest weight-loss effect of any incretin to date.

How long before I see results from Retatrutide?+

Most users track a full Ongoing; weight regain occurs on cessation cycle before judging response. Subjective changes can appear within 1–3 weeks, but objective biomarker shifts typically need the full cycle plus repeat labs.

Is Retatrutide legal?+

Investigational; not yet FDA-approved. Currently available only via clinical trials.

What are the main side effects of Retatrutide?+

Nausea, vomiting, diarrhea (especially during titration); Injection site reactions; Reduced appetite to the point of inadequate protein intake — pair with resistance training and protein targeting; Theoretical pancreatitis and gallbladder risk (class effect).

What should I stack with Retatrutide?+

Commonly combined with: Creatine monohydrate, Whey protein, Vitamin D3 + K2. Introduce one compound at a time to preserve attribution.

What biomarkers should I monitor on Retatrutide?+

Baseline and post-cycle: full blood count, comprehensive metabolic panel, and category-specific markers for metabolic peptides (see the monitoring section on this page).

Can I run Retatrutide back-to-back?+

Off-cycle periods let receptor sensitivity and endogenous feedback normalise. Continuous dosing without a wash-out typically produces diminishing returns and a poorer safety margin.

References

  1. [1]Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial — NEJM, 2023

Further reading: Research library → · Protocols →

Comparison vs Alternatives

Open full comparison →All Peptides →
AttributeRetatrutideThis pageBPC-157MOTS-c
EvidenceGrade AGrade BGrade B
CategoryMetabolicRegenerativeMitochondrial
Best forTriple GIP/GLP-1/glucagon agonistTissue repair, gut integrityMitochondrial signaling
Typical doseTitrated 2 mg → 4 mg → 8 mg → 12 mg250–500 mcg5–10 mg
FrequencyOnce weekly1–2× daily2–3× weekly
RouteSubcutaneous injectionSubcutaneous or oral (gut-localized)Subcutaneous
Legal statusInvestigational; not yet FDA-approved. Currently available only via clinical trials.Not approved by the FDA for human use. Sold as a research chemical in most jurisdictions.Research chemical. Not approved for therapeutic use in humans.
ActionCurrent pageView →View →